EGFR and non-small cell lung carcinoma: The MARIPOSA-2 study [31] compared PFS for amivantamab-lazertinib-chemotherapy, chemotherapy, and amivantamab-chemotherapy in patients with EGFR mutation-positive NSCLC whose disease progressed to osimertinib.